1. Home
  2. MCRB

MCRB

Seres Therapeutics Inc.

Logo Seres Therapeutics Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-12-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.

Founded: 2010 Country:
United States
United States
Employees: 233 City: CAMBRIDGE
Market Cap: 98.9M IPO Year: 2015
Target Price: $6.65 AVG Volume (30 days): 4.0M
Analyst Decision: Hold Number of Analysts: 5
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.89 EPS Growth: N/A
52 Week Low/High: $0.63 - $6.87 Next Earning Date: 05-07-2024
Revenue: $126,325,000 Revenue Growth: 1672.24%
Revenue Growth (this year): -98.9% Revenue Growth (next year): 575.16%

Share on Social Networks: